Press release from the extraordinary shareholders' meeting of Biovitrum (publ)

The information in this press release is not for release, publication
or distribution, directly or indirectly, in or into the United
States, Australia, Canada, Hong Kong, Japan, South Africa,
Switzerland or Singapore.

At the extraordinary shareholders' meeting held on December 4th,
2009, resolutions on  the approval of the board's resolution
regarding the acquisition of Swedish Orphan International Holding AB
and of the board's resolution on a rights issue as well as on an
authorization for the board to resolve on an issue of common shares
and convertible participating certificates (konvertibla
vinstandelsbevis) against payment in kind or by way of set-off, were
adopted. In order to enable the rights issue the meeting also
resolved to amend the articles of association. Further, a new board
member and a new deputy chairman of the board of directors were
elected.

All resolutions by the meeting were caused by the agreement between
Biovitrum and the shareholders of Swedish Orphan International
Holding AB ("Swedish Orphan") pursuant to which Biovitrum shall
acquire 100 per cent of the shares and warrants in Swedish Orphan
(the "Transaction").

Read the whole press release at:
http://www.biovitrum.com/templates/InformationPage.aspx?id=818

For further information, please contact:
Biovitrum AB (publ)

Martin Nicklasson, CEO Biovitrum
Phone: +46 8 697 20 00

Göran Arvidson, CFO Biovitrum
Phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations Biovitrum
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com



About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities
are focused on development and production of biotechnology
therapeutics within our prioritized areas of hemophilia,
inflammation/autoimmune diseases, cancer supportive care and
malabsorption. Biovitrum has revenues of approximately SEK 1.2
billion and approximately 400 employees (prior to the Transaction).
Biovitrum's head office is located in Sweden and the share is listed
on the NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com.

IMPORTANT NOTICE:
The information in this press release is not for release, publication
or distribution, directly or indirectly, in or into the United
States, Australia, Canada, Hong Kong, Japan, South Africa,
Switzerland or Singapore.

The information in this press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of the securities referred to herein in any jurisdiction in
which such offer, solicitation or sale would require preparation of
further prospectuses or other offer documentation, or be unlawful
prior to registration, exemption from registration or qualification
under the securities laws of any such jurisdiction.

The information in this press release does not constitute or form a
part of any offer or solicitation to purchase or subscribe for
securities in the United States. The securities mentioned herein have
not been, and will not be, registered under the United States
Securities Act of 1933 (the "Securities Act"). The securities
mentioned herein may not be offered or sold in the United States
absent registration or an exemption from the registration
requirements of the Securities Act. There will be no public offer of
securities in the United States.

The information in this press release may not be forwarded or
distributed to any other person and may not be reproduced in any
manner whatsoever. Any forwarding, distribution, reproduction, or
disclosure of this information in whole or in part is unauthorized.
Failure to comply with this directive may result in a violation of
the Securities Act or the applicable laws of other jurisdictions.

The above information has been made public in accordance with the
Securities Market Act and/or the Financial Instruments Trading Act.
The information was published at 5.15 p.m. (CET) on December 4th,
2009.